FDA approves vepdegestrant, the first PROTAC degrader ever cleared

## What was approved Vepdegestrant is a PROteolysis TArgeting Chimera, abbreviated PROTAC. The molecule has two functional ends: one binds the estrogen receptor (ER), the other recruits an E3 ubiquitin ligase. The ligase tags the receptor for destruction by the cell's proteasome. The drug acts catalytically. It does not need to occupy the receptor continuously, only to flag it for disposal. Existing agents like fulvestrant destabilise ER but rely on stoichiometric binding; PROTACs degrade the receptor instead. ## The trial VERITAC-2 (NCT05654623) was a global, randomised, open-label Phase 3 trial comparing vepdegestrant to fulvestrant. The pre-specified ESR1-mutated subgroup, the population in which the drug was ultimately approved, comprised 270 patients. All had progressed on at least one prior line of endocrine therapy, typically an aromatase inhibitor with or without a CDK4/6 inhibitor. ## The result Median progression-free survival was 5.0 months on vepdegestrant versus 2.1 months on fulvestrant. The hazard ratio favoured vepdegestrant with a 43% relative reduction in the risk of progression or death. Overall survival data are not yet mature. The full hazard-ratio confidence interval appears in the FDA label. ## Why ESR1 mutations matter Approximately 30 to 40% of patients with ER+/HER2- advanced breast cancer acquire ESR1 mutations after aromatase-inhibitor therapy. These mutations lock the receptor into a constitutively active conformation that fulvestrant binds inefficiently. PROTAC-based degradation bypasses the binding-affinity problem because the receptor needs only to be touched briefly to be flagged for destruction. ## What this means for you The indication is narrow: ER+/HER2-/ESR1m advanced or metastatic breast cancer, post-endocrine therapy. If you or someone close to you sits in this group, ESR1-mutation status should be confirmed by ctDNA liquid biopsy before discussing the drug with the treating oncologist. The platform implication is broader. If PROTACs hold up across follow-on programs, the technology opens previously "undruggable" targets — transcription factors, scaffolding proteins, intrinsically disordered proteins — to selective degradation. ## Caveats VERITAC-2 was open-label, which permits assessor bias on imaging-based progression-free survival. Overall survival is the harder endpoint and remains immature. The median PFS gain of roughly three months is meaningful in a late-line metastatic setting but not curative.